Xiong FF, et al. Protective efficacy of anti-neuraminidase monoclonal antibodies against H7N9 influenza virus infection. Emerg Microbes Infect. 2020 Dec;9(1):78-87
The H7N9 influenza virus has been circulating in China for more than six years. The neuraminidase (NA) has gained great concern for the development of antiviral drugs, therapeutic antibodies, and new vaccines. In this study, we screened seven mouse monoclonal antibodies (mAbs) and compared their protective effects against H7N9 influenza virus. The epitope mapping from escape mutants showed that all the seven mAbs could bind to the head region of the N9 NA close to the enzyme activity sites, and four key sites of N9 NA were reported for the first time. The mAbs D3 and 7H2 could simultaneously inhibit the cleavage of the sialic acid of fetuin protein with large molecular weight and NA-XTD with small molecule weight in the NA inhibition experiment, prevent the formation of virus plaque at a low concentration, and effectively protect the mice from the challenge of the lethal dose of H7N9 virus.
See Also:
Latest articles in those days:
- Cross-species spill-over potential of the H9N2 bat influenza A virus 12 hours ago
- Bat-borne H9N2 influenza virus evades MxA restriction and exhibits efficient replication and transmission in ferrets 12 hours ago
- Epidemiological characteristics of human infections with avian influenza A(H5N6) virus, China and Laos: A multiple case descriptive analysis, February 2014-June 2023 1 days ago
- Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea 2 days ago
- Abundant Intra-Subtype Reassortment Revealed in H13N8 Influenza Viruses 3 days ago
[Go Top] [Close Window]